Non-overweight depressed patients who respond to antidepressant treatment have a higher risk of later metabolic syndrome: findings from the METADAP cohort.

ABSTRACT:

Background

Major depressive disorder (MDD) is a complex disorder with a significant public health burden. Depression remission is often associated with weight gain, a major risk factor for metabolic syndrome (MetS). The primary objective of our study was to assess prospectively the impact of response to antidepressant treatment on developing MetS in a sample of MDD patients with a current major depressive episode (MDE) and who are newly initiating their treatment.

Methods

In the 6-month prospective METADAP cohort, non-overweight patients, body mass index <25 kg/m², with MDD and a current MDE were assessed for treatment response after 3 months of treatment, and incidence of MetS after 3 and 6 months of treatment. Outcome variables were MetS, number of MetS criteria

SUBMITTER: El Asmar K 

PROVIDER: S-EPMC10600935 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature